AKT1 and melanoma: Interestingly, our assessment of the effect of SMG on mTORC1 demonstrates that SMG reduces levels of pAKT (S473), pS6K (S235) and pELF4E (S209) and inhibits cell glycolysis metabolism in melanoma cells, indicating that SMG inhibits the AKT-mTORC1-S6K-ELF4E pathway.